Dr. Floyd is Senior Vice President of Regulatory Affairs and Quality Assurance at Silence Therapeutics. Eric has 24+ years of pharmaceutical and biotechnology experience in Regulatory Affairs roles of increasing responsibility at Merck, Aventis, Novartis, Lundbeck, Axovant Sciences, and Neurogene, Inc. Dr. Floyd has a passion for addressing the unmet medical needs of patients with few to no therapeutic options. Most recently, he served as founder and Chief Regulatory Officer at Neurogene, Inc. Neurogene is focused on developing life-changing genetic medicines for patients and their families affected by rare, devastating neurological diseases. Eric previously served as the Global Head of Regulatory Affairs at Axovant Sciences and the US Head of Regulatory Affairs at Lundbeck, where he was responsible for strategic regulatory and clinical development activities related to the company’s approvals of Sabril, Onfi, Northera (orphan approvals) as well as Anti-Depression and Schizophrenia drug approvals. Eric is the principal and CEO of Floyd Regulatory Strategic Consulting Group, LLC. Dr. Floyd serves as an adjunct faculty member in the Department of Neuroscience at Harvard Medical School and Wake Forest University School of Medicine. He serves as a board member to Virpax Pharmaceuticals, Advent Therapeutics Inc., and is also a member of the Board of Trustees of Meharry Medical College. Dr. Floyd completed his undergraduate degree in Biology from the University of Illinois, a Master’s degree in Neuroscience from Tennessee State University, a Doctorate in Neurophysiology from Meharry Medical College, an Executive MBA in Pharmaceutical Marketing from Saint Josephs’ University, and completed an MBA degree in International Business from the INSEAD Business School in Fountainebleu, France. In his spare time, he enjoys mentoring high school and college students and community service projects of Alpha Phi Alpha Fraternity, Inc.